Sign inJoin waitlistJoin the waitlist

Seema Harichand-Herdt

Medical Oncologist · University of Iowa Health Care Medical Center

Credentials: · · · · · ·

History

Broadlawns Medical Center
2026–Present

Hematology and Medical Oncology
Emory University
2005–2008
Internal Medicine
2002–2005
Univ of Miami Leonard M. Miller Sch of Med
1998–2002

Research

Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline
Journal of Clinical Oncology · 2018 · 191 citations
Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women
Seminars in Oncology · 2009 · First of 2 authors · 45 citations
Endocrine therapy for the treatment of postmenopausal women with breast cancer
Review · Expert Review of Anticancer Therapy · 2009 · First of 3 authors · Corresponding · 16 citations

Ruth O’Regan
3 papers
Amelia Zelnak
2 papers
Suresh Ramalingam
2 papers
Ash Alpert
1 paper
Calvin Chou
1 paper
Carole Fakhry
1 paper
Christopher Lathan
1 paper
Diana Bell
1 paper
ES
Erich Sturgis
1 paper
Jose Zevallos
1 paper
Lisa Rooper
1 paper
Mark Lingen
1 paper

Clinical trials

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2029
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
Site PI · Recruiting · Phase 3
NRG Oncology
2026–2035
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2026–2040
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2026–2038